Objective: To estimate the comparative efficacy among antiepileptic drugs in the pediatric population (0-18 years). Methods: Using the Embase and MEDLINE databases, we updated to February 2017 the search strategy of the National Institute for Health and Care Excellence guidelines for epilepsy. We only included randomized clinical trials conducted in children and mixed-age populations. According to the PRISMA network metaanalysis guideline, the study-level quality assessment was made with the Cochrane risk-of-bias tool. Three investigators independently selected articles. The efficacy outcome was considered to be seizure freedom or ≥50% seizure reduction. Results: We selected 46 randomized clinical trials. A total of 5652 individuals were randomized to 22 antiepileptic drugs and placebo. The point estimates of carbamazepine and lamotrigine efficacy showed their superiority with respect to all comparator antiepileptic drugs for the treatment of newly diagnosed focal epilepsy. In refractory focal epilepsy, levetiracetam (odds ratio [OR] = 3.3, 95% credible interval [CrI] = 1.3-7.6) and perampanel (OR = 2.5, 95% CrI = 1.1-5.8) were more effective compared to placebo. Ethosuximide and valproic acid were both superior to lamotrigine against absence seizures. The OR point estimate showed the superiority of adrenocorticotropic hormone over all comparators in infantile spasms. A wide heterogeneity in the length of follow-up was observed among the studies. Significance: This network meta-analysis suggests that the quality of studies should be improved through the use of comparative designs, relevant outcomes, appropriate follow-up length, and more reliable inclusion criteria. 
In 2011, the National Institute for Health and Care Excellence (NICE) published an update to the guidelines on the management of epilepsy in adult and pediatric patients, according to seizure and syndrome type. 6 We updated the NICE guideline from September 2010 to February 2017, focusing on pharmacological treatment in children and adolescents, and including studies conducted in pediatric and mixed populations. Due to the small sample size of available randomized clinical trials (RCTs) and the paucity of comparative studies, we decide to perform a network meta-analysis (NMA).
| MATERIALS AND METHODS

| Search strategy and selection criteria
The NICE search strategy was updated in the Embase and MEDLINE databases up to February 24, 2017 . The following terms were combined using the Boolean operator "or": "epilep*," "continuous spike wave of slow sleep," "Landau-Kleffner syndrome," "Lennox-Gastaut syndrome," ("infant*" and "spasms*"), "seizure*," and "convulsion*" in the title/abstract or the Medical Subject Heading term "Epilepsy." Systematic reviews, RCTs, and observational studies were selected according to the NICE search strategy. English language and pediatric age (0-18 years) were also used as filters. Only RCTs conducted in pediatric (0-18 years) and mixed populations were included in the NMA. Additionally, the reference list of the previous NICE review was searched to identify RCTs that met the inclusion criteria and were published before June 2010. RCTs conducted on mixed populations were included only when the outcome efficacy was available for pediatric age or the mean age of patients enrolled was <18 years. The protocol is registered with PROSPERO, number CRD42015024920.
| Data analysis
The following data were extracted for each study included: journal and year of publication, funder, seizure and syndrome type, demographics, study characteristics, number of randomized and treated patients, type and dosage of drugs, monotherapy or add-on therapy, and efficacy and safety outcome. The studies included were meta-analyzed according to syndromic classification whenever possible, thus considering the following conditions: newly diagnosed focal epilepsy, refractory focal epilepsy, infantile spasms-West syndrome, Dravet syndrome, Lennox-Gastaut syndrome, childhood absence epilepsy, juvenile absence epilepsy, self-limited epilepsy with centrotemporal spikes (ECTS), and juvenile myoclonic epilepsy. Seizure freedom, when reported, or ≥50% seizure reduction from baseline to the last evaluation was considered as the efficacy outcome. If necessary (inhomogeneous outcome data across studies), seizure freedom was used as a proxy of ≥50% seizure reduction. The number of individuals with seizure freedom or ≥50% seizure reduction and the total number of patients in each treatment group were extracted for each study. Study-level quality was assessed using the items reported in the Cochrane risk-of-bias tool (random sequence generation, allocation concealment, blinding of participants, outcome assessment, incomplete data, and selective reporting). 7 Three investigators (L.I., G.C., A.P.) independently screened titles and abstracts and analyzed full texts. Any disagreements were resolved by discussion and consensus of a panel of other investigators within the review team. All the information from the selected articles was inputted into an ad hoc dataset to perform statistical analysis. We performed NMA with the aim of simultaneously analyzing both direct comparisons of interventions within trials (subject of conventional pairwise meta-analysis) and indirect comparisons across trials based on a common comparator (eg, placebo or some standard treatment). 8, 9 If the efficacy of 2 interventions, A and B, is to be compared but no studies are available comparing them, indirect evidence can be Key Points
• Our network meta-analysis is the first one entirely dedicated to pediatrics and reporting results on the basis of syndrome and/or seizure types
• We found a superiority of CBZ and LTG in the treatment of newly diagnosed focal epilepsy, of ETS in absence epilepsy, and of ACTH and corticosteroids in infantile spasms
• Our results provide valuable information needed to design a rational research agenda 298 | obtained by studying either A or B versus a common comparator. When both direct and indirect evidence are available (mixed comparison), the information can be combined. For mixed-treatment comparison, we performed a random-effects NMA within a Bayesian framework, using the freely available GeMTC (Generate Mixed Treatment Comparisons) R package (https://CRAN.R-project.org/package=-gemtc). 10, 11 We simultaneously ran 4 chains with different arbitrarily chosen initial values, with a variance scaling factor of 2.5. Convergence and lack of autocorrelation were checked and confirmed after 20 000 iterations with thinning interval equal to 1, followed by 50 000 iterations to estimate parameters. We used default noninformative values for priors and default values for likelihood and link function (suitable for the data). We assessed treatment effect using odds ratios (ORs) and their 95% credible intervals (CrIs), the Bayesian equivalent to confidence intervals (CIs). For direct comparison, we performed a random-effect pairwise meta-analysis within frequentist approach, using the freely available "meta" R package (https://CRAN.Rproject.org/package=meta). 12 We assessed treatment effect using ORs and their 95% CIs. For both mixed and direct estimations, we considered an intervention as superior to another if the OR > 1 and corresponding 95% CrI (Bayesian analyses) or 95% CI (frequentist analyses) does not include 1.
We sorted league tables presenting direct and mixed evidence using the treatment deemed as the clinical standard or that with the best performance in terms of point estimate as a reference (top left corner).
We assessed inconsistencies between direct and indirect sources of evidence by calculating the difference between direct and indirect estimates in all closed loops in the network, whenever possible (direct comparisons in at least 2 studies). We assessed statistical heterogeneity in each pairwise comparison with the I² statistic and P value (direct comparisons in at least 2 studies). A P value < .05 was considered statistically significant.
We drew network maps using the network map STATA (version 14) command. These maps showed which drugs are directly compared with each other, and roughly how much information is available for each drug and for each comparison.
To determine whether the results were affected by the choice of Bayesian approach, we performed sensitivity analysis by estimating mixed treatment comparisons using a frequentist approach. Additional sensitivity analysis considered only seizure freedom outcome and studies with low risk of bias. In particular, we considered only domains with a low risk of bias in at least 50% of studies and with at least 50% of studies having a low risk of bias for each syndrome.
We assessed safety by evaluating the percentage of withdrawals due to adverse events (AEs).
| RESULTS
We selected a total of 4302 RCTs through the research strategy applied to the Embase and MEDLINE databases, also including 129 references from the NICE guideline. Forty-six RCTs were included in the qualitative synthesis; 43 articles were analyzed for efficacy outcome (Figure 1 ).
Six studies included newly diagnosed epilepsy with focal or generalized seizures, and 10 RCTs were conducted in refractory focal epilepsy. According to the syndromic classification, 2 RCTs were included on ECTS, 14 on infantile spasms-West syndrome, 6 on Lennox-Gastaut syndrome, 5 on childhood absence epilepsy and juvenile absence epilepsy, 1 on Dravet syndrome, and 2 on juvenile myoclonic epilepsy ( Table 1 
| Risk of bias
Attrition bias was the most frequent bias observed (28 studies were judged to be high risk), followed by performance (19 studies), and detection bias (15 studies). Allocation concealment and random sequence generation were the more poorly reported domains, with 14 and 8 studies, respectively, being judged to have an unclear level of risk. Selective reporting or other quality domains were judged to have a low risk of bias ( Figure S1 ).
| Efficacy
| Newly diagnosed focal epilepsy
Four of the six studies enrolling untreated patients with focal seizures were meta-analyzed. [13] [14] [15] [16] [17] [18] Two studies were excluded from the network due to different outcome measures 15 and the absence of a common comparator. 13 In the 4 meta-analyzed studies, a total of 642 individuals (age range = 2-17 years) were randomized to CBZ, PHT, PB, VPA, LTG, or OXC and followed for 24 weeks to 4 years ( Table 1 ). The most frequent drug studied was CBZ ( Figure 2A ). The seizure freedom outcome was considered in all studies. Direct and mixed comparisons did not show differences in efficacy among AEDs (Table 2A Table 2A and Figure 3A ). No evidence of heterogeneity or inconsistency was found. Attrition bias was the most frequently observed bias ( Figure S1A ).
| Refractory focal epilepsy
Nine of the 10 studies enrolling patients with refractory focal epilepsy were meta-analyzed. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] The Duchowny study 21 was excluded from the network, as seizure reduction outcome was missing. From the 9 meta-analyzed studies, a total of 1591 individuals (age range = 3-17 years) were randomized to add-on OXC, TPM, LEV, GPT, ZNS, PER, or PLB. Patients were followed for 1 to 28 weeks ( Figure 2B ). Direct comparisons showed that all AEDs with the exception of TPM and GPT were more effective than PLB in terms of ≥50% seizure reduction (Table 2B) . Only LEV (OR = 3.3, 95% CrI = 1.3-7.6) and PER (OR = 2.5, 95% CrI = 1.1-5.8) were more effective compared to PLB in mixed comparisons (Table 2B and Figure 3B ). Considering seizure freedom outcome, none among the AEDs analyzed (TPM, LEV, OXC, and PER) was better than PLB in direct comparison, whereas in mixed comparisons only TPM showed a superiority compared to PLB (Table 2C and Figure 3C ). No evidence of heterogeneity or inconsistency was found. Attrition bias was the most frequently observed bias ( Figure S1B ).
| Self-limited ECTS
Only 2 RCTs enrolling patients with ECTS were selected (Table 1) . 29, 30 No meta-analysis was feasible due to the absence of common comparators. Coppola et al. 29 failed to demonstrate a superiority of LEV compared to OXC (OR = 1.42, 95% CI = 0.61-20.00) as first-line treatment in 39 individuals (mean age of almost 9 years) followed for 18 months. Rating et al. 30 found a better efficacy of STM compared with PLB in terms of seizure freedom (OR = 10.42, 95% CI = 3.29-33.03) in 66 patients (mean age of almost 8 years). Attrition bias was observed in the 2 selected studies ( Figure S1C ).
| Childhood absence epilepsy and juvenile absence epilepsy
Four of the 5 studies on untreated patients with childhood absence epilepsy and juvenile absence epilepsy were metaanalyzed (Table 1) . [31] [32] [33] [34] [35] One study was excluded from the network due to the absence of a common comparator (Figure 2C) . 33 A total of 623 individuals (age range = 2.6-15 years) were randomized to ETS, VPA, LTG, or LEV and followed for 2 weeks to 4 years ( Table 1) . Seizure freedom was the outcome considered in all RCTs. VPA was the most frequently studied drug ( Figure 2C ). ETS and VPA did not show a difference in terms of seizure freedom in both direct and mixed comparisons. LTG was less effective than ETS in direct (OR = 0.32, 95% CI = 0.19-0.54) and mixed comparisons (OR = 0.34, 95% CrI = 0.13-0.95; Table 2D and Figure 3D ). LTG was also less effective than VPA in direct (OR = 0.36, 95% CI = 0.23-0.59) and mixed (OR = 0.37, 95% CrI = 0.15-0.92) comparisons (Table 2D and Figure 3D ). No evidence of heterogeneity or inconsistency was found. Attrition bias was the most frequently observed bias ( Figure S1D ).
| Juvenile myoclonic epilepsy
Two studies enrolling patients with juvenile myoclonic epilepsy were selected and meta-analyzed. 36, 37 A total of 71 individuals (age range = 9-43 years) were randomized to either TPM or VPA monotherapy and followed for 24-26 weeks (Table 1) ; seizure freedom was the outcome considered in both studies. No differences were found between TPM and VPA (OR = 1.39, 95% CI = 0.48-4.04), and no evidence of heterogeneity was found. Performance, detection, and attrition biases were observed in the 2 selected studies ( Figure S1E ).
| Infantile spasms-West syndrome
Fourteen studies enrolling patients with infantile spasms were meta-analyzed. [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] A total of 1218 infants (age range = 0-24 months) were randomized to ACTH, prednisolone, prednisone, GVG, NZP, TPM, LEV, or PLB and followed for 1 week to 6.4 months ( Table 1 ). The seizure freedom outcome was assessed in 12 RCTs. Most studies evaluated the efficacy of corticosteroids (prednisone and prednisolone) and ACTH, which was the most frequent comparator ( Figure 2D ). Considering the ≥50% seizure reduction outcome, no differences were found among all the molecules in mixed comparisons (Table 2 and Figure 3E) . Only GVG was less effective than ACTH (OR = 0.41, 95% CI = 0.20-0.86) in direct comparisons, and standard doses of GVG were better than low-dose GVG. Significant heterogeneity was found among the studies comparing ACTH and corticosteroids. Considering the seizure freedom outcome (Table 2F) , no superiority of ACTH was demonstrated in mixed comparison, although the OR point estimate showed its superiority over all comparators ( Figure 3F) ; direct comparisons were in agreement with the results found for the ≥50% seizure reduction outcome (Table 2F ). Significant heterogeneity but not inconsistency was found among the studies comparing ACTH and corticosteroids. Performance and detection biases were those most frequently observed ( Figure S1F ).
| Lennox-Gastaut syndrome
Five of the six studies on patients with Lennox-Gastaut syndrome were meta-analyzed. [52] [53] [54] [55] [56] [57] Among the 5 RCTs, a total of 717 individuals (age range = 4-37 years) were randomized to add-on CLB, LTG, TPM, FBM, RUF, or PLB and followed for 10-16 weeks ( Table 1) . Reduction of seizure frequency ≥50% was reported in 4 RCTs. All studies included used PLB as the comparator (Figure 2E) . In direct estimations, RUF, LTG, and CLB were better than PLB. Only TPM showed superiority compared to PLB in mixed comparison (OR = 1.4e+11, 95% CrI = 15-1.1e+28). TPM was also more effective than RUF, FBM, LTG, and CLB in mixed comparison (Table 2G and Figure 3G ). Attrition bias was the most frequently observed bias ( Figure S1G ).
| Dravet syndrome
Only 1 study enrolling patients with Dravet syndrome was selected. Chiron et al. 58 randomized 42 individuals (age range = 3-20 years) to STP or PLB as add-on, and followed them for 2 months ( Table 1 ). The outcome considered was seizure freedom and was obtained in 43% (9/21) of patients on STP compared to 0% of the 20 individuals in the PLB group (OR = 31.16, 95% CI = 1.66-583.26). This study was classified as having a low risk of bias ( Figure S1H ).
| Sensitivity analysis
A sensitivity analysis was possible and performed for frequentist approach and low risk of bias, as well as for the previously reported seizure freedom outcome. No difference was found when data were analyzed according to a frequentist approach (Table S1 ) and low risk of bias (Table S2) .
| Safety
Twenty-two studies of the 46 analyzed reported safety information about the withdrawal rate related to AEs (Table 3) . A rate of withdrawal > 10% was reported for PB, VPA, PHT, CBZ, and CLB. LTG had a better safety profile compared to CBZ (Table 3) .
| DISCUSSION
The limited information available on the efficacy of AEDs in pediatric epilepsy, which is in turn the consequence of the small number of RCTs, indicates that more comparative studies are needed to bridge the gap in knowledge. It is perhaps due to this lack of information that an NMA on the treatment of epilepsy in the pediatric population has not been attempted before, despite the relevance of the topic. The paucity of RCTs is the main finding of our NMA. However, the NMA strengthens the information emerging from each single study. 59 Although absence of differences in efficacy between the different AEDs is likely to primarily reflect flaws in the statistical and study design, it cannot be excluded that real differences in efficacy might at times not exist. CBZ and LTG emerged as the most effective AEDs for treating newly diagnosed focal epilepsy, although the CrI of the estimated OR did not show superiority. However, the NMA failed to demonstrate a superiority of LTG compared to CBZ, as reported in the SANAD study, conducted on both children and adults. 60 No AED except for LEV, PER, and TPM was found to be superior to PLB in achieving ≥50% reduction in seizure frequency (primary outcome) in patients with refractory focal epilepsy. More comparative RCTs are needed to confirm the efficacy profiles of LTG, and LEV, PER, and TPM treatment in newly diagnosed and refractory focal epilepsies, respectively. No conclusive results emerged from the 2 studies enrolling patients with ECTS, a "benign" condition with a self-limiting course for which treatment can be avoided altogether and further research may not be necessary, at least in the noncomplicated forms, which represent the great majority of cases. 61 More higher quality studies are instead necessary to assess the best treatment approach to the "atypical forms." ETS and VPA were better than LTG in treating epilepsy with absence seizures, 62 whereas TPM and VPA showed similar efficacy in juvenile myoclonic epilepsy. Considering the recent EMA restrictions on the use of VPA in the female population, ETS and TPM seem to be the only first-line treatments for absence seizures and juvenile myoclonic epilepsy, respectively, in this population. 63 No relevant information about safety profile of the AEDs were retrieved by RCTs included in our NMA.
Considering the specificity and complexity of pediatric epilepsies, we decided to include only studies reporting results by age group or enrolling patients with a mean age < 18 years, differently from other 2 recent NMA including mixed populations, 68, 69 in which no subgroup analysis for pediatric age was performed. Our inclusion criteria may have excluded RCTs with useful information on AED efficacy, especially in focal epilepsy, for which EMA and FDA recognize the direct transferability of the results of adult studies to the pediatric population due to a similar clinical expression in children and adults. 2, 3 Conversely, our inclusion criteria guarantee a better external validity by excluding RCTs enrolling a mixed population. Limits in internal and external validity affect most of the RCTs analyzed. Most of the studies included in the NMA were of low quality, with short and heterogeneous follow-ups and outcomes of limited clinical relevance. The appropriateness of a ≥50% reduction in seizure frequency has been questioned by the National Institute for Health and Care Excellence, which strongly recommends more clinically relevant outcome measures such as, for example, seizure freedom. 6 However, the clinical relevance of a ≥50% reduction in seizure frequency may be considered in severe conditions with countless seizures or when seizure freedom is unrealistic, such as infantile spasms or Lennox-Gastaut syndrome, as well as most epileptic encephalopathies. In any case, the majority of Lennox-Gastaut syndrome studies consider the ≥50% reduction only for drop attack seizures, neglecting the global seizure burden. Moreover, most of the recently introduced AEDs have been tested in placebo-controlled adjunctive therapy trials performed in patients who did not respond to 1, 2, or more AEDs, and in which the causes of previous treatment failures (ie, AED appropriateness, dosing, duration of treatment, and adherence) were poorly documented.
This NMA highlights the tight limits of the current knowledge guiding the pharmacological treatment of pediatric epilepsy and the consequent considerable arbitrariness on which the choice of medications is based in most syndromes. To bridge the lack of knowledge, the regulatory agencies EMA and FDA are developing guidance regarding the factors influencing the extrapolation of adult efficacy data to pediatric patients. Great attention is dedicated to the similarities and differences between adults and children in terms of disease progression and response to intervention, and different extrapolation approaches are based on available pharmacokinetic and pharmacodynamic knowledge. 70, 71 In epilepsy, the extrapolation approach is at present applied to focal epilepsies, based on an assumed similar exposureresponse relationship in pediatric and adult patients with partial onset seizures. 70, 71 In our opinion, however, the guidance algorithm is not evidence-based and lacks reliable tools to assert close similarities between adults and children in terms of disease progression and response to intervention. For example, a recent position paper of the Pediatric Epilepsy Academic Consortium for Extrapolation 72 backs the extrapolation based on a single meta-analysis 73 of differences in efficacy between AEDs and placebo, conducted on 30 RCTs, of which only 6 were carried out in a pediatric population. 73 This meta-analysis estimated differences in responder rates (≥50% seizure reduction) to range from 2.0% to 43.0% in adults and from 3.0% to 26.0% in children. Our NMA has generated data, and evidence for paucity of data, that will hopefully be instrumental in stimulating the debate on how to improve the quality of studies through comparative designs, more reliable inclusion criteria, more relevant outcomes, and appropriate follow-ups. We also believe the extrapolation process in pediatric epilepsy should not be simply based on poorly documented inferences but would rather benefit from a dedicated research agenda.
